Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
Thrombopoietin (TPO)
Overview
Thrombopoietin is a 332-amino acid endogenous glycoprotein hormone and the primary physiologic regulator of megakaryopoiesis and platelet production. It binds to the c-Mpl receptor on megakaryocyte progenitors and mature megakaryocytes, stimulating their proliferation, differentiation, and platelet release.
Mechanism of Action
Recombinant TPO and pegylated recombinant megakaryocyte growth and development factor (PEG-rHuMGDF) were developed but abandoned after clinical trials revealed antibody-mediated thrombocytopenia.
Research Summary & Key Findings
Early clinical trials of recombinant TPO in the 1990s showed efficacy in chemotherapy-induced thrombocytopenia, but development was halted after healthy volunteers and cancer patients developed neutralizing antibodies that cross-reacted with endogenous TPO, causing severe thrombocytopenia. This experience led to development of non-immunogenic TPO receptor agonists such as romiplostim and eltrombopag that do not share sequence homology with native TPO.
Clinical Status
Thrombopoietin (TPO) is in the investigational stage. While preclinical and early-phase data exist, it has not received regulatory approval for clinical use in the United States.
Administration Routes
References
Primary literature
- PubMed: "Thrombopoietin"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "Thrombopoietin"
Registered interventional and observational studies, including status and phase.
- PubChem: "Thrombopoietin"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Hematology
Bivalirudin (Angiomax)
FDA ApprovedA synthetic 20-amino acid peptide that acts as a direct thrombin inhibitor by binding both the catalytic active site and...
View detailsRomiplostim (Nplate)
FDA ApprovedA thrombopoietin (TPO) receptor agonist consisting of a peptide sequence that binds the TPO receptor (c-Mpl) fused to an...
View detailsPegcetacoplan (Empaveli)
FDA ApprovedA pegylated cyclic peptide that inhibits complement component C3, the central node of all three complement activation pa...
View detailsPeginesatide (Omontys)
FDA ApprovedPeginesatide is a synthetic pegylated peptide-based erythropoiesis-stimulating agent (ESA) consisting of two 21-amino ac...
View detailsNo lawful pathway today
Thrombopoietin (TPO) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.